Nuvo Pharmaceuticals Inc NRIFF

RE: RE: RE: RE: RE: RE: cheerleaders for 1/2 price

[HippygirL74]

Dear Philly1 and consultant99,  Good questions and good points respectively.  i am thinking that by April there really will be no need for a consolidation.  It really doesn't matter what exchange we trade on.  The only thing that matters is that the balance sheet looks good with lots of cash.  Cash attracts all kinds of small and insignificant advanced apes.  If Pennsaid establishes a nice little market and starts taking market share away from the patch and that greasy gel (Vulgar Gel or something like that) from the competition, the stage will be set for Pennsaid Plus (gel). 

Toronto TSX is very respectable and anyone can invest here.  Trading on an American exchange has a lot of fees to pay too.  i really don't think it is the exchange that matters but the cash and revenue earning ability that matters.   Sorry, i don't think,  i know.  We could trade on the Venture exchange.  It doesn't matter.  Only earnings matter.  So lets vote like heck to stop a consolidation.  And i like to have fun so let's scare the hell out of the shorts and cancel any consolidation ideas.   We should create chaos for the shorts just for the heck of it.  And if in the future it really is an option we can change our minds later.

Besides, if Covidien buys us out, and i really think they will, why even bother trading on another exchange.  We might all have cash or Covidien shares.  So there you have it, we'll be on the NYSE indirectly. 

As for the buy-out price, well that all depends on how much in gross revenues Pennsaid and Pennsaid Plus and the other drugs can generate.  Net revenues are too creative.  A good accountant can get the net down significantly.  So NRI will sell for a multiple of Gross revenues.  If growth is high, maybe NRI will be worth 3X Gross revenues and the cash on hand is extra.  That's why in a lot of takeovers, the cash is taken out of the equation and distributed to the shareholders in the form of a special dividend, otherwise the buyer gets the cash and buys the company with the cash on hand. 

But any buyout will not happen for some time imo.  i think Covidien will want low risk so they will pay a much higher price once sales are proven.  Of course this means it will cost them a lot more, but they need to justify the risk / reward with their own shareholders first.  Current NRI management is not getting any younger and family and health issues will be a gentle motivator.  It will be a friendly takeover imo.  The rights to Pennsaid Plus belong to NRI.  It's worth big bucks and significantly more than 0.17 per share assuming we get FDA approval of course.